Plasma amyloid-β oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer's dementia: Findings from the GMCII cohort.
Yuhan Xie, Xue Meng, Tao Li, Haifeng Zhang, Yaonan Zheng, SangYun Kim, Chen Zhang, Xin Yu, Huali Wang
{"title":"Plasma amyloid-β oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer's dementia: Findings from the GMCII cohort.","authors":"Yuhan Xie, Xue Meng, Tao Li, Haifeng Zhang, Yaonan Zheng, SangYun Kim, Chen Zhang, Xin Yu, Huali Wang","doi":"10.1002/dad2.70064","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to explore the association between plasma amyloid-β oligomerization tendency (OAβ) and cognitive performance in Alzheimer's disease (AD) and determine its predictive value for outcomes of mild cognitive impairment (MCI).</p><p><strong>Methods: </strong>Plasma from 727 subjects (286 AD, 260 MCI, and 181 controls) in a case registry was analyzed using the multimer detection system (MDS) to measure plasma OAβ.</p><p><strong>Results: </strong>Elevated plasma OAβ was strongly correlated with multidomain cognitive performance in patients with MCI and AD. Patients with MCI with high baseline plasma OAβ demonstrated a higher risk of progressing to dementia (hazard ratio = 1.083, 95% confidence interval [CI] 1.032-1.137). Baseline plasma OAβ effectively predicted MCI-dementia conversion (area under the curve [AUC] = 0.824, 95% CI 0.752-0.897).</p><p><strong>Discussion: </strong>The real-world findings underscore the clinical relevance of plasma OAβ as a potential predictor for the conversion from mild cognitive impairment (MCI) to dementia.</p><p><strong>Highlights: </strong>We recruit study participants of Alzheimer's dementia (AD), mild cognitive impairment (MCI), and cognitively normal controls in a case registry.We use the multimer detection system (MDS) to measure plasma amyloid-β oligomerization tendency (OAβ).We observe that elevated plasma OAβ strongly correlates with multidomain cognitive performance in patients with MCI and AD.MCI individuals with high baseline plasma OAβ demonstrate a higher risk of progressing to dementia.The real-world findings underscore the clinical relevance of plasma Oaβ as a potential predictor for the conversion from MCI to dementia.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 1","pages":"e70064"},"PeriodicalIF":4.0000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848609/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70064","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: This study aimed to explore the association between plasma amyloid-β oligomerization tendency (OAβ) and cognitive performance in Alzheimer's disease (AD) and determine its predictive value for outcomes of mild cognitive impairment (MCI).
Methods: Plasma from 727 subjects (286 AD, 260 MCI, and 181 controls) in a case registry was analyzed using the multimer detection system (MDS) to measure plasma OAβ.
Results: Elevated plasma OAβ was strongly correlated with multidomain cognitive performance in patients with MCI and AD. Patients with MCI with high baseline plasma OAβ demonstrated a higher risk of progressing to dementia (hazard ratio = 1.083, 95% confidence interval [CI] 1.032-1.137). Baseline plasma OAβ effectively predicted MCI-dementia conversion (area under the curve [AUC] = 0.824, 95% CI 0.752-0.897).
Discussion: The real-world findings underscore the clinical relevance of plasma OAβ as a potential predictor for the conversion from mild cognitive impairment (MCI) to dementia.
Highlights: We recruit study participants of Alzheimer's dementia (AD), mild cognitive impairment (MCI), and cognitively normal controls in a case registry.We use the multimer detection system (MDS) to measure plasma amyloid-β oligomerization tendency (OAβ).We observe that elevated plasma OAβ strongly correlates with multidomain cognitive performance in patients with MCI and AD.MCI individuals with high baseline plasma OAβ demonstrate a higher risk of progressing to dementia.The real-world findings underscore the clinical relevance of plasma Oaβ as a potential predictor for the conversion from MCI to dementia.
期刊介绍:
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.